Philipp Erben

Mannheim, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 109 publications

Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy.

Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy.

Journal: Urologic oncology
Published: September 25, 2025

The bladder cancer m6A landscape is defined by global methylation dilution and focal 3'-UTR hypermethylation.

The bladder cancer m6A landscape is defined by global methylation dilution and focal 3'-UTR hypermethylation.

Journal: EMBO reports
Published: July 09, 2025

Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial Cancer.

Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial Cancer.

Journal: European urology open science
Published: April 17, 2025

Unicorns transforming the practice of urology: value creation and allocation in the digital age.

Unicorns transforming the practice of urology: value creation and allocation in the digital age.

Journal: World journal of urology
Published: March 26, 2025

Proliferation and regeneration of the healthy human urothelium: A multi-scale simulation approach with 16 hypotheses of cell differentiation.

Proliferation and regeneration of the healthy human urothelium: A multi-scale simulation approach with 16 hypotheses of cell differentiation.

Journal: PloS one
Published: October 11, 2024

Loss of YTHDC1 m6A reading function promotes invasiveness in urothelial carcinoma of the bladder.

Loss of YTHDC1 m6A reading function promotes invasiveness in urothelial carcinoma of the bladder.

Journal: Experimental & molecular medicine
Published: May 24, 2024

Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC Monitor.

Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC Monitor.

Journal: BJU international
Published: May 08, 2024

Prognostic significance of EGFR, AREG and EREG amplification and gene expression in muscle invasive bladder cancer.

Prognostic significance of EGFR, AREG and EREG amplification and gene expression in muscle invasive bladder cancer.

Journal: Frontiers in oncology
Published: January 25, 2024

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.

Journal: Oncoimmunology
Published: October 23, 2023

An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder Cancer.

An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder Cancer.

Journal: Urologia internationalis
Published: October 18, 2023

Reinvestigating the clinical relevance of the m6A writer METTL3 in urothelial carcinoma of the bladder.

Reinvestigating the clinical relevance of the m6A writer METTL3 in urothelial carcinoma of the bladder.

Journal: iScience
Published: March 02, 2023

An m6A-Driven Prognostic Marker Panel for Renal Cell Carcinoma Based on the First Transcriptome-Wide m6A-seq.

An m6A-Driven Prognostic Marker Panel for Renal Cell Carcinoma Based on the First Transcriptome-Wide m6A-seq.

Journal: Diagnostics (Basel, Switzerland)
Published: January 31, 2023
Showing 1-12 of 109

Last Updated: 09/26/2026